33318177|t|Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin.
33318177|a|Intraocular pressure-sensitive retinal ganglion cell degeneration is a hallmark of glaucoma, the leading cause of irreversible blindness. Here, we used RNA-sequencing and metabolomics to examine early glaucoma in DBA/2J mice. We demonstrate gene expression changes that significantly impact pathways mediating the metabolism and transport of glucose and pyruvate. Subsequent metabolic studies characterized an intraocular pressure (IOP)-dependent decline in retinal pyruvate levels coupled to dysregulated glucose metabolism prior to detectable optic nerve degeneration. Remarkably, retinal glucose levels were elevated 50-fold, consistent with decreased glycolysis but possibly including glycogen mobilization and other metabolic changes. Oral supplementation of the glycolytic product pyruvate strongly protected from neurodegeneration in both rat and mouse models of glaucoma. Investigating further, we detected mTOR activation at the mechanistic nexus of neurodegeneration and metabolism. Rapamycin-induced inhibition of mTOR robustly prevented glaucomatous neurodegeneration, supporting a damaging role for IOP-induced mTOR activation in perturbing metabolism and promoting glaucoma. Together, these findings support the use of treatments that limit metabolic disturbances and provide bioenergetic support. Such treatments provide a readily translatable strategy that warrants investigation in clinical trials.
33318177	10	17	glucose	Chemical	MESH:D005947
33318177	22	30	pyruvate	Chemical	MESH:D019289
33318177	45	53	glaucoma	Disease	MESH:D005901
33318177	78	86	pyruvate	Chemical	MESH:D019289
33318177	90	99	rapamycin	Chemical	MESH:D020123
33318177	101	112	Intraocular	Disease	MESH:D064090
33318177	132	166	retinal ganglion cell degeneration	Disease	MESH:D012162
33318177	184	192	glaucoma	Disease	MESH:D005901
33318177	228	237	blindness	Disease	MESH:D001766
33318177	302	310	glaucoma	Disease	MESH:D005901
33318177	314	320	DBA/2J	CellLine	CVCL:6496
33318177	321	325	mice	Species	10090
33318177	443	450	glucose	Chemical	MESH:D005947
33318177	455	463	pyruvate	Chemical	MESH:D019289
33318177	511	522	intraocular	Disease	MESH:D064090
33318177	567	575	pyruvate	Chemical	MESH:D019289
33318177	607	614	glucose	Chemical	MESH:D005947
33318177	646	670	optic nerve degeneration	Disease	MESH:D009410
33318177	692	699	glucose	Chemical	MESH:D005947
33318177	790	798	glycogen	Chemical	MESH:D006003
33318177	888	896	pyruvate	Chemical	MESH:D019289
33318177	921	938	neurodegeneration	Disease	MESH:D019636
33318177	947	950	rat	Species	10116
33318177	955	960	mouse	Species	10090
33318177	971	979	glaucoma	Disease	MESH:D005901
33318177	1016	1020	mTOR	Gene	56717
33318177	1060	1077	neurodegeneration	Disease	MESH:D019636
33318177	1094	1103	Rapamycin	Chemical	MESH:D020123
33318177	1126	1130	mTOR	Gene	56717
33318177	1150	1180	glaucomatous neurodegeneration	Disease	MESH:D019636
33318177	1225	1229	mTOR	Gene	56717
33318177	1280	1288	glaucoma	Disease	MESH:D005901
33318177	Association	MESH:D005947	MESH:D005901
33318177	Association	MESH:D005901	56717
33318177	Negative_Correlation	MESH:D019289	MESH:D064090
33318177	Negative_Correlation	MESH:D020123	56717
33318177	Association	MESH:D019636	56717
33318177	Association	MESH:D005947	MESH:D020123
33318177	Association	MESH:D005947	MESH:D064090
33318177	Negative_Correlation	MESH:D020123	MESH:D019636
33318177	Association	MESH:D019289	MESH:D005901
33318177	Association	MESH:D005947	MESH:D019289
33318177	Association	MESH:D005947	MESH:D009410
33318177	Negative_Correlation	MESH:D020123	MESH:D005901
33318177	Cotreatment	MESH:D019289	MESH:D020123
33318177	Negative_Correlation	MESH:D019289	MESH:D019636

